H Lundbeck A/S (LUN.CO)
21 Jul 2017
* Lundbeck and Takeda receive complete response letter from the FDA for Trintellix® (vortioxetine) sNDA
* SIGNS DEAL WITH BIOTECH COMPANY IMMUNOBRAIN CHECKPOINT, INC. (IBC) FOR RIGHTS TO RESEARCH IN TREATMENT OF ALZHEIMER'S DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
May 10 Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday.
* 2017 GUIDANCE RAISED BASED ON STRONG REVENUE GROWTH AND IMPROVED PROFITABILITY
* LUNDBECK ENTERS A CONDITIONAL AGREEMENT AND DIVESTS PART OF ITS HEADQUARTERS IN COPENHAGEN AND EXPECTS TO RAISE ITS FINANCIAL GUIDANCE BY DKK 200 MILLION
* OTSUKA AND LUNDBECK ANNOUNCE IMPROVEMENT OF AGITATION SYMPTOMS RELATED TO ALZHEIMER’S-TYPE DEMENTIA FOLLOWING TREATMENT WITH BREXPIPRAZOLE RELATIVE TO PLACEBO
BRIEF-Health Canada approves Otsuka and Lundbeck's REXULTI as a treatment for schizophrenia in adults
* Health Canada approves Otsuka and Lundbeck's REXULTI(tm) (brexpiprazole) as a treatment for schizophrenia in adults
Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
Feb 8 Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
* Not concerned about the policies of U.S. President Donald Trump.